Skip to main content
. 2024 Mar 13;9(6):1817–1835. doi: 10.1016/j.ekir.2024.03.014

Figure 6.

Figure 6

Anticipated response to inhibition of selected drug targets in patients with active lupus nephritis (LN). Bars depict proportions of patients with an anticipated benefit from inhibition of selected drug targets across LN patient subgroups. BTK, Bruton’s tyrosine kinase; hi, high; IFN, interferon; IFNAR, interferon-α/β receptor; im, intermediate; JAK, Janus kinase; LN, lupus nephritis; lo, low; mTORC1, mammalian target of rapamycin complex 1.